AAV Integrity Analysis by Nanopore Sequencing
With extensive experience in both academia and industry, the AAVnerGene team excels at delivering a reliable platform for AAV characterization and analysis. Our in-depth knowledge and expertise enable us to offer comprehensive services that go beyond standard quality control measures, helping researchers ensure the precision, reliability, and effectiveness of their AAV vectors.
Price and Turnaround
| Method | Purpose | Turnaround | Price | Sample Requirement |
| Denature Gel | Size assessment | 1-2 day | $200/sample | ~100 μl of sample with titer >1E+12vg/ml |
| TapStation | Size assessment | 1-2 day | $200/sample | ~100 μl of sample with titer >1E+12vg/ml |
| CD-MS | Size assessment | 3-4 weeks | Request | ~100 μl of sample with titer >1E+12vg/ml |
| NGS-Illumina | Sequence details | 3-4 weeks | Request | ~100 μl of sample with titer >1E+12vg/ml |
| NGS-Pacbio | Sequence details | 3-4 weeks | Request | ~100 μl of sample with titer >1E+12vg/ml |
| NGS-Nanopore | Sequence details | 2-3 weeks | Starting from $600 | ~100 μl of sample with titer >1E+12vg/ml |
AAV Genomic Integrity
Genomic integrity refers to the completeness and accuracy of the AAV genome, which includes the transgene cassette and the flanking inverted terminal repeats (ITRs). The ITRs are critical for replication, packaging, and integration of the viral genome, while the transgene cassette contains the therapeutic gene and regulatory elements necessary for its expression. Any alterations, deletions, or rearrangements in the AAV genome can compromise the functionality of the vector, leading to reduced therapeutic efficacy or even safety concerns.
AAV genomic integrity is not just a technical detail—it is the foundation of successful gene therapy. By ensuring that AAV vectors deliver complete and accurate genomes, researchers and manufacturers can maximize therapeutic efficacy, minimize safety risks, and bring life-changing treatments to patients. As the field evolves, continued focus on improving genomic integrity will be essential to unlocking the full potential of AAV-based gene therapies.
To address this, AAVnerGene provides a variety of advanced analytical methods to assess AAV genomic integrity, including TapeStation, denaturing gel electrophoresis, charge detection mass spectrometry (CD-MS), PacBio or Nanopore next generation sequencing (NGS).
NGS for AAV Genome Analysis
- High Resolution: NGS provides base-by-base sequence information, enabling the detection of even minor defects.
- Comprehensive Coverage: It can analyze the entire AAV genome, including ITRs, transgene sequences, and regulatory elements.
- Detection of Structural Variants: NGS can identify insertions, deletions, rearrangements, and other structural variants that may impact genome integrity.
- Quantitative Analysis: NGS can quantify the relative abundance of different genome variants, providing insights into population heterogeneity.
- Identification of Contaminants: NGS can detect impurities, such as host cell DNA or replication-competent AAV (rcAAV), ensuring the purity of the final product.
Ensuring the integrity of the AAV genome is critical for the safety and efficacy of gene therapies, and NGS offers a comprehensive solution for this purpose. NGS offers several advantages for AAV genome analysis:
Several NGS technologies are available, including Illumina, PacBio, and Nanopore sequencing.
- Illumina: Ideal for high-throughput, cost-effective analysis of small variants and quantitative studies. Illumina sequencing is the most widely used NGS platform, known for its high accuracy, high throughput, and cost-effectiveness. It uses a sequencing-by-synthesis approach to generate short reads (typically 50-300 bp).
- PacBio: Best for full-length genome analysis and resolving complex regions like ITRs. PacBio sequencing, also known as Single-Molecule Real-Time (SMRT) Sequencing, generates long reads (up to 20 kb) by sequencing individual DNA molecules in real time. It is particularly well-suited for resolving complex genomic regions.
- Nanopore: Suitable for ultra-long reads, real-time sequencing, and portable applications. Nanopore sequencing, developed by Oxford Nanopore Technologies, is a third-generation sequencing platform that generates ultra-long reads (up to hundreds of kb) by measuring changes in electrical current as DNA strands pass through a nanopore.
Nanopore Sequencing for AAV vectors
Nanopore sequencing offers a powerful, real-time, low cost and long-read sequencing platform that enables comprehensive characterization of AAV vector genomes at single-molecule resolution. Unlike short-read technologies, nanopore sequencing can read full-length AAV genomes, including both single-stranded and self-complementary forms, and directly identify structural variants, ITR integrity, and unwanted host or plasmid-derived contaminants.
